The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2026 | Predicting Richter transformation in CLL: the role of genomic biomarkers
Anna Schuh, MD, PhD, University of Oxford, Oxford, UK, discusses the potential of genomic biomarkers to identify patients with chronic lymphocytic leukemia (CLL) at increased risk of Richter transformation. Professor Schuh highlights the association of NOTCH1 mutations and stereotyped B-cell receptor subset 8 with transformation risk, alongside emerging research using single-cell analysis and methylation clocks, while emphasizing the need for clinically actionable interventions before introducing more intensive monitoring. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
